Literature DB >> 33724157

Cell-free DNA methylome profiling by MBD-seq with ultra-low input.

Jinyong Huang1, Alex C Soupir1, Liang Wang1.   

Abstract

Methylation signatures in cell-free DNA (cfDNA) have shown great sensitivity and specificity in the characterization of tumour status and classification of tumour types, as well as the response to therapy and recurrence. Currently, most cfDNA methylation studies are based on bisulphite conversion, especially targeted bisulphite sequencing, while enrichment-based methods such as cfMeDIP-seq are beginning to show potential. Here, we report an enrichment-based ultra-low input cfDNA methylation profiling method using methyl-CpG binding proteins capture, termed cfMBD-seq. We optimized the conditions for cfMBD capture by adjusting the amount of MethylCap protein along with using methylated filler DNA. Our data show high correlation between low input cfMBD-seq and standard MBD-seq (>1000 ng input). When compared to cfMEDIP-seq, cfMBD-seq demonstrates higher sequencing data quality with more sequenced reads passed filter and less duplicate rate. cfMBD-seq also outperforms cfMeDIP-seq in the enrichment of CpG islands. This new bisulphite-free ultra-low input methylation profiling technology has great potential in non-invasive and cost-effective cancer detection and classification.

Entities:  

Keywords:  Liquid biopsies; MBD-seq; cfDNA; low input DNA; methylome; next-generation sequencing

Mesh:

Substances:

Year:  2021        PMID: 33724157      PMCID: PMC8920199          DOI: 10.1080/15592294.2021.1896984

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  38 in total

1.  Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias.

Authors:  Shalima S Nair; Marcel W Coolen; Clare Stirzaker; Jenny Z Song; Aaron L Statham; Dario Strbenac; Mark D Robinson; Susan J Clark
Journal:  Epigenetics       Date:  2011-01-01       Impact factor: 4.528

2.  Whole-genome DNA methylation profiling using MethylCap-seq.

Authors:  Arie B Brinkman; Femke Simmer; Kelong Ma; Anita Kaan; Jingde Zhu; Hendrik G Stunnenberg
Journal:  Methods       Date:  2010-06-11       Impact factor: 3.608

Review 3.  Epigenetics in cancer.

Authors:  Manel Esteller
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 4.  Current and future perspectives of liquid biopsies in genomics-driven oncology.

Authors:  Ellen Heitzer; Imran S Haque; Charles E S Roberts; Michael R Speicher
Journal:  Nat Rev Genet       Date:  2019-02       Impact factor: 53.242

5.  Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Rui-Hua Xu; Wei Wei; Michal Krawczyk; Wenqiu Wang; Huiyan Luo; Ken Flagg; Shaohua Yi; William Shi; Qingli Quan; Kang Li; Lianghong Zheng; Heng Zhang; Bennett A Caughey; Qi Zhao; Jiayi Hou; Runze Zhang; Yanxin Xu; Huimin Cai; Gen Li; Rui Hou; Zheng Zhong; Danni Lin; Xin Fu; Jie Zhu; Yaou Duan; Meixing Yu; Binwu Ying; Wengeng Zhang; Juan Wang; Edward Zhang; Charlotte Zhang; Oulan Li; Rongping Guo; Hannah Carter; Jian-Kang Zhu; Xiaoke Hao; Kang Zhang
Journal:  Nat Mater       Date:  2017-10-09       Impact factor: 43.841

Review 6.  Integrating liquid biopsies into the management of cancer.

Authors:  Giulia Siravegna; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2017-03-02       Impact factor: 66.675

7.  Methylome analysis using MeDIP-seq with low DNA concentrations.

Authors:  Oluwatosin Taiwo; Gareth A Wilson; Tiffany Morris; Stefanie Seisenberger; Wolf Reik; Daniel Pearce; Stephan Beck; Lee M Butcher
Journal:  Nat Protoc       Date:  2012-03-08       Impact factor: 13.491

8.  Enrichment methods provide a feasible approach to comprehensive and adequately powered investigations of the brain methylome.

Authors:  Robin F Chan; Andrey A Shabalin; Lin Y Xie; Daniel E Adkins; Min Zhao; Gustavo Turecki; Shaunna L Clark; Karolina A Aberg; Edwin J C G van den Oord
Journal:  Nucleic Acids Res       Date:  2017-06-20       Impact factor: 16.971

Review 9.  Cell-Free DNA Methylation Profiling Analysis-Technologies and Bioinformatics.

Authors:  Jinyong Huang; Liang Wang
Journal:  Cancers (Basel)       Date:  2019-11-06       Impact factor: 6.639

10.  MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments.

Authors:  Matthias Lienhard; Christina Grimm; Markus Morkel; Ralf Herwig; Lukas Chavez
Journal:  Bioinformatics       Date:  2013-11-13       Impact factor: 6.937

View more
  4 in total

1.  Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA.

Authors:  Jinyong Huang; Alex C Soupir; Brian D Schlick; Mingxiang Teng; Ibrahim H Sahin; Jennifer B Permuth; Erin M Siegel; Brandon J Manley; Bruna Pellini; Liang Wang
Journal:  Cancers (Basel)       Date:  2021-11-09       Impact factor: 6.639

2.  cfDNA methylome profiling for detection and subtyping of small cell lung cancers.

Authors:  Francesca Chemi; Simon P Pearce; Alexandra Clipson; Steven M Hill; Alicia-Marie Conway; Sophie A Richardson; Katarzyna Kamieniecka; Rebecca Caeser; Daniel J White; Sumitra Mohan; Victoria Foy; Kathryn L Simpson; Melanie Galvin; Kristopher K Frese; Lynsey Priest; Jacklynn Egger; Alastair Kerr; Pierre P Massion; John T Poirier; Gerard Brady; Fiona Blackhall; Dominic G Rothwell; Charles M Rudin; Caroline Dive
Journal:  Nat Cancer       Date:  2022-08-08

Review 3.  Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures.

Authors:  Angela Oberhofer; Abel J Bronkhorst; Carsten Uhlig; Vida Ungerer; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2022-07-29

Review 4.  Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer.

Authors:  Sasha C Main; David W Cescon; Scott V Bratman
Journal:  Cancer Drug Resist       Date:  2022-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.